News
Home > News > News
2017/09/21
CCSB obtained TW patent for Ixazomib citrate intermediate
The Taiwanese Patent Office has granted Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) a process patent on the API manufacturing of Ixazomib citrate on September 21, 2017. The patent “PROCESS FOR PREPARING INTERMEDIATE COMPOUND OF IXAZOMIB CITRATE, AND IXAZOMIB CITRATE MADE THEREBY” (I 599571) is based on proprietary technology developed by CCSB, including novel manufacture method and solutions to previous issues such as reduction of impurities in ixazomib citrate intermediate to obtain high quality ixazomib citrate intermediate and ixazomib citrate. In addition, the patent technology improves API product purity and production yield.
